Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to the BNF newsletter

Newsletter
August 2020

Welcome to the August BNF eNewsletter.

• One new drug monograph has been added to the BNF in the last month: fostamatinib.
• MHRA advice on apixaban, cyproterone acetate, dabigatran etexilate, edoxaban and rivaroxaban.

Kind regards,
BNF Team

Other topics:

Significant changes   |   Drug Safety Update   |   BNF80   |   BNFC 2020-2021   |   BNF app

Significant changes

BNF BNF only

New monograph: Tavlesse® [fostamatinib] for chronic immune thrombocytopenia in patients refractory to other treatments.

New preparation: Lenzetto® [estradiol] for menopausal symptoms.

New preparation: Spravato® [esketamine] for induction and maintenance of anaesthesia, analgesic supplementation of regional and local anaesthesia, analgesia in emergency medicine, major depressive disorder and major depressive disorder (patients of Japanese origin).

Deleted monograph: Collagenase

Deleted monograph: Pergolide

Apixaban: Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, availability of reversal agents [MHRA/CHM advice].

Cyproterone acetate: new advice to minimise risk of meningioma [MHRA/CHM advice].

Dabigatran etexilate: Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, availability of reversal agents [MHRA/CHM advice].

Edoxaban: Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, availability of reversal agents [MHRA/CHM advice].

Emtricitabine with tenofovir disoproxil for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection [AWMSG guidance].

Fremanezumab for preventing migraine [NICE guidance].

Rivaroxaban: Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, availability of reversal agents [MHRA/CHM advice].

Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [NICE guidance].

Ustekinumab for treating moderately to severely active ulcerative colitis [NICE guidance].

Venous thromboembolism: updated guidance for the treatment of venous thromboembolism.

Dose changes for BNF only
Atovaquone with proguanil hydrochloride [update to dosing for prophylaxis of malaria].

Mefloquine [update to dosing for prophylaxis of malaria].

Omeprazole [update to dosing for acid reflux disease].

Proguanil hydrochloride [update to dosing for prophylaxis of malaria].

BNF for Children BNF for Children Only

Dose changes for BNF for Children
Doxycycline [update to dosing for prophylaxis of malaria].

Proguanil hydrochloride [update to age range for prophylaxis of malaria].

Solifenacin succinate [update to include child dosing].

Tipranavir [dose removed for child 2-11 years as oral solution formulation discontinued].

BNF BNF for Children Both BNF and BNF for Children

Deleted monographs: Stavudine.

Genital system infections, antibacterial therapy: updated guidance for the management of uncomplicated gonorrhoea.

Ketotifen for the symptomatic treatment of seasonal allergic conjunctivitis [AWMSG guidance].

Smallpox vaccine: updated guidance in-line with Public Health England recommendations.

Dose changes for BNF and BNF for Children
Azithromycin [update to dosing for uncomplicated gonorrhoea].

Ceftriaxone [update to dosing for gonococcal infections].

Chloroquine [update to dosing for prophylaxis of malaria].

Ciprofloxacin [update to dosing for gonococcal infections].

 
Drug Safety Update
 

Drug Safety Update is a monthly newsletter from the MHRA and Commission on Human Medicine. Please follow this link to review the latest Drug Safety Update.

Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection

Liposomal and lipid-complex formulations: name change to reduce medication errors

 
 

News

BNF 80 now available

The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care. The new edition (BNF 80) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.

978-0-85711-370-2 | August 2020 | 1712pp | £59.95

Extensive content updates in the new edition include new monographs on:

Beovu ® [brolucizumab] for neovascular (wet) age-related macular degeneration
Cytotect ® [cytomegalovirus immunoglobulin] for prophylaxis of cytomegalovirus infection in patients taking immunosuppressants, particularly transplant recipients
Mayzent ® [siponimod] for multiple sclerosis [secondary progressive, with active disease]
   
BNF 80

MHRA advice on:

Etonogestrel (Nexplanon ®) contraceptive implants: new insertion site to reduce rare risk of neurovascular injury and implant migration
Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy
Ulipristal acetate (Esmya ®): suspension of the licence due to risk of serious liver injury
   
Order now

BNF for Children 2020-21 now available

The British National Formulary for Children is the first choice for concise medicines information for children. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.

The new edition provides up-to-date guidance on prescribing, dispensing, and administering medicines to children, plus legal and professional guidelines.

978-0-85711-372-6 | August 2020 | 1222pp | £59.95

Extensive content updates in the new edition include:

New monographs on:

BNFC 2020-2021
Gilenya ® [fingolimod] for multiple sclerosis
Mozobil ® [plerixafor] to mobilise haematopoietic stem cells to peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma or solid malignant tumours
Renapime ® [cefepime] for bacterial infection
   

Dose changes:

Epipen ® preparations (adrenaline/epinephrine) [body-weight ranges for children's dosing updated]
Idursulfase [updated age range]
   
Order now

Get ready for the improved BNF app

The British National Formulary (BNF) app helps busy healthcare professionals access essential medicines information quickly, offline and on-the-go.

Used by around 200,000 healthcare professionals every month, it continues to be a vital resource for those prescribing, dispensing and administering medicines.

If you've already downloaded the BNF app and switched on automatic updates, you will get instant access to the improved version. Otherwise, simply update your app to access the improved version.

BNF App
What can I look forward to?

Colour-coded content
BNF and BNF for Children content will be colour-coded with clear labelling. You can easily differentiate between adult and child content and identify the right information for your patient; blue for BNF and pink for BNF for Children.

Intuitive design
The thoughtful design updates support the selection of safe and effective medicines – search Interactions with one click and swiftly move from section to section with the new menu.

Learn more about the BNF app

Please donate old copies of the BNF

The PharmAid Scheme is an initiative of the Commonwealth Pharmacists Association where recent versions of medicines information resources including the BNF are redistributed to low and middle income countries. You can make a difference in another commonwealth country by simply donating your old BNF copies to them.

For more information on this scheme see commonwealthpharmacy.org/what-we-do/pharmaid/. If you would like to donate your copy email: admin@commonwealthpharmacy.org.

 
 

How to purchase BNF

 
Print

Print
online

Online
Subscription

Subscription
 
 
 

Newsletter Feedback
Please let us know if there are any issues that you'd like us to address in our newsletters. We welcome your feedback. If you have any comments or suggestions, please let us know at marketing@rpharms.com.

Sign up to receive the BNF newsletter

Copyright © 2020 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved.

Terms of use

Copyright © 2020 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved.

If you want to unsubscribe from emails from Pharmaceutical Press click here .

Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.